First Hawaiian Bank Acquires 82 Shares of BIO-TECHNE Corp (TECH)

First Hawaiian Bank raised its holdings in BIO-TECHNE Corp (NASDAQ:TECH) by 59.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 219 shares of the biotechnology company’s stock after purchasing an additional 82 shares during the quarter. First Hawaiian Bank’s holdings in BIO-TECHNE were worth $43,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Deutsche Bank AG raised its position in shares of BIO-TECHNE by 197.1% in the fourth quarter. Deutsche Bank AG now owns 159,043 shares of the biotechnology company’s stock worth $23,013,000 after acquiring an additional 105,512 shares during the period. American Century Companies Inc. raised its position in shares of BIO-TECHNE by 331.1% during the 4th quarter. American Century Companies Inc. now owns 156,965 shares of the biotechnology company’s stock worth $22,716,000 after purchasing an additional 120,557 shares during the last quarter. Geode Capital Management LLC raised its position in shares of BIO-TECHNE by 7.1% during the 4th quarter. Geode Capital Management LLC now owns 416,496 shares of the biotechnology company’s stock worth $60,275,000 after purchasing an additional 27,587 shares during the last quarter. Norges Bank acquired a new position in shares of BIO-TECHNE during the 4th quarter worth about $70,995,000. Finally, Actinver Wealth Management Inc. acquired a new position in shares of BIO-TECHNE during the 4th quarter worth about $537,000. 94.08% of the stock is currently owned by institutional investors.

TECH stock opened at $201.50 on Monday. The stock has a market capitalization of $7.64 billion, a price-to-earnings ratio of 49.51, a price-to-earnings-growth ratio of 4.57 and a beta of 1.25. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.35 and a quick ratio of 3.31. BIO-TECHNE Corp has a 12 month low of $132.75 and a 12 month high of $206.04.

BIO-TECHNE (NASDAQ:TECH) last posted its quarterly earnings results on Tuesday, February 5th. The biotechnology company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.08. BIO-TECHNE had a net margin of 14.02% and a return on equity of 13.90%. The business had revenue of $174.50 million during the quarter, compared to analysts’ expectations of $171.39 million. During the same quarter in the prior year, the company posted $1.02 EPS. The business’s revenue for the quarter was up 13.2% on a year-over-year basis. On average, sell-side analysts expect that BIO-TECHNE Corp will post 3.68 earnings per share for the current year.

TECH has been the subject of a number of recent research reports. Argus reiterated a “buy” rating on shares of BIO-TECHNE in a report on Monday, March 4th. BidaskClub upgraded shares of BIO-TECHNE from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Craig Hallum reiterated a “hold” rating and issued a $179.00 price objective (up previously from $154.00) on shares of BIO-TECHNE in a report on Tuesday, February 5th. Zacks Investment Research upgraded shares of BIO-TECHNE from a “sell” rating to a “hold” rating in a report on Saturday, January 5th. Finally, Stephens upgraded shares of BIO-TECHNE from an “equal weight” rating to an “overweight” rating and set a $180.00 price objective for the company in a report on Monday, January 14th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $188.13.

TRADEMARK VIOLATION NOTICE: “First Hawaiian Bank Acquires 82 Shares of BIO-TECHNE Corp (TECH)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.com-unik.info/2019/04/15/first-hawaiian-bank-acquires-82-shares-of-bio-techne-corp-tech.html.

About BIO-TECHNE

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.

Featured Story: Return on Investment (ROI)

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BIO-TECHNE Corp (NASDAQ:TECH).

Institutional Ownership by Quarter for BIO-TECHNE (NASDAQ:TECH)

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit